Member Info for CHELSEA7

Again Dracula much like another share, factually totally wrong!! The high from 12 months ago has come down from 13p to 11.25, today so it is more like 50% down, not 20% and from the low of 3.7 a few months ago we are 100% higher at 7,25!!! So not near bottom at all.

Did you actually think the share would increase dramatically on todays news? I didn"t, but hoping sincerely the abstracts are well digested by the Oncology market, that will in time we hope impress the market and share holders old and new.

Think news of patients recruited and dosed will see a little rise, and the potential for deals from the abstracts today could well be seen in the coming year. Lets hope so.

Still offering 7.075 for 215k+ after a 60k sell. They seemed so reluctant to move up, and from 6.865 to 7.075 was quite some leap, so hoping we see a few blue trades to follow.

7/7.50

A 3K BUY at 7.32......................a welcome sight!!

Scancell News Update, just received at 10.59..............

Latest News Update

Please find below a link to the latest News Update from Scancell.

https://www.scancell.co.uk/scancell-to-present-six-posters-at-the-cri-cimt-eati-aacr-international-cancer-immunotherapy-conference

I rather think one way or another Scancell shareholders are all aware of whats happening this week

MMs have just jumped to 7.075 for 215k......................wonder why?

MMs still taking 215k+ at 6.865 same price as it fell slightly to yesterday after the 37k sell. A 70k buy at 7.13 today.

So the real spread is about 3.5/4%, indicitive spread 10.29%

So we get the RNS and this on Twitter too diresct to Scancell website.

https://www.scancell.co.uk/scancell-to-present-six-posters-at-the-cri-cimt-eati-aacr-international-cancer-immunotherapy-conference

Indeed that is an enormous amount of work from Scancell, lets hope it is that good

Just out of interest why did you post me this.......................

Hi C7,
Whilst its very apparent we a polar opposites in our views regarding the board

Have I ever said that?? Nope. What I have been trying to say, and for once being diplomatic, lol, is you have been quick to have a go at the BOD at every opportunity of late. And I don"t agree with certain things you have said. I am sure PR has been working very closely with those in the Oncology world, and I guess I have accepted we the PIs are the last consideration of the BOD in these matters. I was just like you are now, but if they had of RNSed the abstracts today, would we have risen 10-15%?? Well I wouldn"t have sold anyway, 50p+ changes my life, not 7-10p. So bring on the trials, data and possible licensing deals, that will take us where we want to be hopefully and like the third platform, that goes back to pre 2015, but we only hear now. Which IMHO makes your opinion about the BOD being inept etc etc, just a few posts back, your opinion not mine. So we are not poles apart, we both want the same thing, perhaps I am being more realistic now. ATB

Glad you posted that, had seen a similar article elsewhere recently. I have a lot of faith in that appointment, and I think a few people asked why Scancell?? Good explanation.

Agree with that Bermuda, hence I was surprised, I have seen another Biotech this week RNSing abstracts at a different conference.

25k Buy at 7p?

Still taking 215k+ at 6.865

Crumbs, is that Paul Rennart?? I just don"t use Twitter. Well done McBlue.

Thanks Bermuda, so I am not surprised any more. Funny enough from the brochure I only recognised 3 names, presentations 2 x 26/9 and the other the 27th, so was rather hoping after being told there were six that was the case.

Who was it that posted that on Twitter??

Well obviously not, a bit surprised really...................

Yesterday at the close.................MMsTue 15:54
Taking up to 70k at 6.877, over that and above 215k 6.865....................

Courtesy of the Scancell Website, an 8 page PDF full of good information about our third platform. Well worth a read..................

https://www.scancell.co.uk/Data/Sites/1/media/publications/news/scancell-update-040919_final.pdf

The number of securities in issue:
The company has an issued share capital of 465,355,867 ordinary shares of 0.1p each, all of which are called up and fully paid.

Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 3,184,630 ordinary shares to ICHOR at 4.5p per share.

Directors’ Share Options:
The Company has granted the following options to Directors of the Company.

Option holder Option price per ordinary share Number of ordinary shares under option Last day of exercise period
Sally Adams 10.5p 2,500,000 30 January 2028
John Chiplin 17.0p 3,000,000 18 April 2026
Lindy Durrant 4.5p 3,850,000 14 July 2020
Lindy Durrant 10.5p 9,000,000 30 January 2028
Richard Goodfellow 4.5p 2,880,000 14 July 2020
Richard Goodfellow 33.2p 3,500,000 31 December 2023
Clifford Holloway 10.5p 3,000,000 30 January 2028


In addition to the above, the Company has granted options over 1,396,016 shares of the Company to various other persons at exercise prices between 5p and 33.2p.

As at 16 August 2019 the percentage of AIM securities not in public hands was: 31.50%

Identity and percentage holdings of significant shareholders:
As at 16 August 2019 the identity and percentage holdings of significant shareholders were:

Ordinary shares at 0.1p each
Number Percentage
Vulpes Life Science Fund 77,559,311 16.67%
Calculus Capital 49,844,165 10.71%
Scancell Holdings plc directors and related holdings 19,163,147 4.12%

Nothing like an update, eh.......................

Will be surprised if there isn"t one TBH. We see quite a few biotechs doing the same with even individual abstracts showing at events, six from Scancell says an enormous amount about the work going on at HQ.

Wonder if any update is due about patient recruitment? It was August 19th that the first patient was enrolled, 5 weeks later we would have expected a few more, and even after five weeks the first patient would be due treatment, you would have thought. I didn"t catch any timelines that may have been suggested at the AGM, was there any??

An interesting post Dracula, the word ""luckily" has been used twice, and whilst not here to correct minor details like Vulpes investing £4 not circa £3m, after having us researched for five years and putting us through the hardest due diligance some have seen, they took advantage of a lower SP in securing their stake, as did numerous other PIs in snapping up the 21m shares that City Financial had to dispose of.. Many have seen a tremendous return and rather than luck well done to them, an investment opportunity arose and they piled in. To get to trials an enormous amount of work is done from concept to clinical development. I think today will be a proud day, having six abstracts on show, showing all of us the vast array of work being done by Team Scancell, which we never get to hear about, which leads to much criticism of the BOD on occasions. ""Lucky"" not a word i feel we have had our fair share of yet, and hoping CICON19 goes well for us, where our science goes on display.

I particularly liked this post by Bermuda yesterday, helping us to understand the functions of the abstracts on display,........

Bermudashorts

Posts: 10,213

Price: 7.05

No Opinion

RE: CICON 19 ABSTRACTSTue 07:00
Interesting - very quick summary based on my understanding of each abstract. Purely IMO of course and I'm sure others will explain in more detail :)

A046 - relates to glycan mAB FG2811 and shows that it can activate TSCMs (stem memory T cells) with the potential to use them to create TCR/CAR T therapies

A185 - seems to be a summary of Modi1's MOA

A201 - GRP78 is a heat shock protein which is linked to autophagy and highly expressed in tumours. Citrullinated GRP78 is a potential target for Moditope - is this Modi3?

A212 - relates to Moditope. Blood from cancer patients and healthy volunteers was cultured with citrullinated/homocitrullinated peptides. Difference between the 2 groups suggests regulatory T cells (Tregs) may suppress immune response in some cancer patients - may need to be inhibited.

B203 - Modi2 and homocitrullination. Worth noting the role of MDSCs (myeloid derived suppressor cells) - highly immunosuppressive cells that are associated with a very poor prognosis and 'cold tumours'. The beauty of Modi2 is that these cells express MPO which generates Isocyanic acid which diffuses into the tumour and drives homocitrullination. So Moditope cleverly exploits MDSCs.

B223 - use of PEP-FOLD3 software which uses algos to screen and select epitopes for Moditope

ReplyRecommend (12)

I often post news about Oncimmune our Notts Uni neighbours and subject to a collaboration with us two years ago. A nice appointment for them.....................

https://www.fiercebiotech.com/biotech/sethi-to-leave-astrazeneca-to-take-up-oncimmune-post?mkt_tok=eyJpIjoiWmpoa09EUXlaVFUzTkRBNCIsInQiOiJUN0FENnR1UHJQMCtIeURJZnRMR1NHQzZYcFNWd0hxUEN0dTdOWVI4ajYwNlwvZU5TWGw3REc3RU4yMU9WcGJcL0xBQ1l4ZTRUeTluWlArdmhmSk04RnliMGU4RGRcL1RwcEdpZzZHUFwvcGdnSkRoTSt3cklmN1pNT01VdUVrZEQ3d2YifQ%3D%3D&mrkid=36433381

Catch yer tomorrow. Night.

Yeah thanks Bermuda, as I said was just curious.